Some great summaries here on this thread for Leslie’s interview...

Some great summaries here on this thread for Leslie’s interview with Dani from Proactive Investors.  A recurring theme is safety, lack of toxicity & something that was repeated multiple times, COMBINATION therapy.  

IMU pipeline includes multiple indications, albeit at earlier stages than their lead candidate HER-VAXX.  Will we be seeing combination trials with T cell vaccines (ie Keytruda) which is still in ongoing trials to increase indications for Merck’s multi-billion dollar drug & B cell vaccines as an adjunct immunotherapy to increase immune response in cancer in the near future +/- chemotherapy?  This is something I got as a possibility from the interview in regards to ‘beautiful combinations’, & purely IMO.  

Aside from this, exceptionally pleased with the announcement that IMU will have 3 poster presentations at AACR & research published.  That’s impressive.  We will all get to read these once the embargo is lifted on presentations.  GLTAH